Stockholm-based Annexin Pharmaceuticals has recently obtained FDA approval for the company's phase II study in RVO, a production patent in the US, and a patent agreement with Stanford University regarding the cancer area. The latter means stronger product protection in the US and the opportunity to broaden their project portfolio and develop ANXV as a treatment for cancer. BioStock contacted the company's CMO and co-founder, Anna Frostegård, to find out more.

Read the full article about Annexin Pharmaceuticals at biostock.se:

https://www.biostock.se/en/2022/05/annexins-cmo-on-patent-strategy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/annexin-pharmaceuticals-ab/r/biostock--annexin-s-cmo-on-patent-strategy,c3570480

(c) 2022 Cision. All rights reserved., source Press Releases - English